Medtronic (NYSE:MDT – Get Free Report) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 5.440-5.500 for the period, compared to the consensus estimate of 5.450. The company issued revenue guidance of $33.5 billion-$33.6 billion, compared to the consensus revenue estimate of $33.6 billion. Medtronic also updated its FY25 guidance to $5.44-5.50 EPS.
Wall Street Analysts Forecast Growth
A number of research firms have weighed in on MDT. Needham & Company LLC restated a “hold” rating on shares of Medtronic in a report on Monday. Stifel Nicolaus upped their price objective on Medtronic from $85.00 to $87.00 and gave the stock a “hold” rating in a research note on Wednesday, August 21st. Robert W. Baird cut their target price on Medtronic from $96.00 to $93.00 and set a “neutral” rating on the stock in a research note on Wednesday. Barclays increased their price target on shares of Medtronic from $104.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, August 22nd. Finally, Daiwa America raised shares of Medtronic to a “strong-buy” rating in a research report on Friday, August 23rd. One analyst has rated the stock with a sell rating, nine have issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Medtronic currently has a consensus rating of “Hold” and a consensus target price of $95.19.
Get Our Latest Analysis on Medtronic
Medtronic Trading Down 1.0 %
Medtronic (NYSE:MDT – Get Free Report) last released its quarterly earnings results on Tuesday, November 19th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.25 by $0.01. The business had revenue of $8.40 billion for the quarter, compared to the consensus estimate of $8.27 billion. Medtronic had a net margin of 13.00% and a return on equity of 13.79%. The business’s revenue was up 5.2% on a year-over-year basis. During the same period in the previous year, the firm earned $1.25 EPS. As a group, equities research analysts expect that Medtronic will post 5.46 EPS for the current year.
Medtronic Company Profile
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
Featured Stories
- Five stocks we like better than Medtronic
- What Are Trending Stocks? Trending Stocks Explained
- Is Biotech’s Bull Run Over? Examining Election Impacts
- Differences Between Momentum Investing and Long Term Investing
- 3 Stocks Generating a Ridiculous Amount of Cash
- What is Insider Trading? What You Can Learn from Insider Trading
- Dividend Growth Meets Chips: Top 3 Semiconductor Stocks to Watch
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.